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Abstract
Background
Identifying cognitively healthy people at high risk of developing dementia is an ever-increas-
ing focus. These individuals are essential for inclusion in observational studies into the natu-
ral history of the prodromal and early disease stages and for interventional studies aimed at
prevention or disease modification. The success of this research is dependent on having
access to a well characterised, representative and sufficiently large population of individu-
als. Access to such a population remains challenging as clinical research has, historically,
focussed on patients with dementia referred to secondary and tertiary services. The primary
care system in the United Kingdom allows access to a true prodromal population prior to
symptoms emerging and specialist referral. We report the development and recruitment
rates of the CHARIOT register, a primary care-based recruitment register for research into
the prevention of dementia. The CHARIOT register was designed specifically to support
recruitment into observational natural history studies of pre-symptomatic or prodromal
dementia stages, and primary or secondary prevention pharmaceutical trials or other pre-
vention strategies for dementia and other cognitive problems associated with ageing.
Methods
Participants were recruited through searches of general practice lists across the west and
central London regions. Invitations were posted to individuals aged between 60 and 85
years, without a diagnosis of dementia. Upon consent, a minimum data set of demographic
and contact details was extracted from the patient’s electronic health record.
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Results
To date, 123 surgeries participated in the register, recruiting a total of 24,509 participants–a
response rate of 22.3%. The age, gender and ethnicity profiles of participants closely match
that of the overall eligible population. Higher response rates tended to be associated with
larger practices (r = 0.34), practices with a larger older population (r = 0.27), less socioeco-
nomically disadvantaged practices (r = 0.68), and practices with a higher proportion of
White patients (r = 0.82).
Discussion
Response rates are comparable to other registers reported in the literature, and indicate
good interest and support for a research register and for participation in research for the pre-
vention of age-related neurodegenerative diseases and dementia. We consider that the
simplicity of the approach means that this system is easily scalable and replicable across
the UK and internationally.
Introduction
There are currently more than 35 million people worldwide living with dementia and, due to
the ageing world population, this number is expected to double by 2030 and more than triple
by 2050 to exceed 115 million [1]. The total cost of the management of dementia was estimated
to be US$604 billion in 2010 [2] and in addition to the increasing morbidity, a recent study has
shown that mortality associated specifically with Alzheimer’s dementia (AD) may be higher
than previously thought [3].
In order to effectively address this major health and socioeconomic challenge, public fund-
ers and charities worldwide have identified research into causative pathways and risk factors
for dementia, as well as drug discovery and development of new and effective disease-modify-
ing therapies, as a high research priority [4]. The licensing of cholinesterase inhibitors in the
late 1990’s for the symptomatic treatment of Alzheimer’s dementia, together with initial publi-
cations unravelling the role of the amyloid cascade and tau, were the principal catalysts in an
enthusiastic wave of drug discovery and development towards targeted disease-modifying ther-
apies for this devastating condition. More than a decade later, these attempts have proven dis-
appointing as new compounds, typically tested in patients at an advanced stage of Alzheimer’s
dementia, have failed at various stages of development–with a failure rate of 99.6% of potential
agents [5]. Coupled with these disappointing results, there is now recognition that the AD-type
pathological changes start accumulating years, if not decades, prior to the onset of dementia. In
predominantly inherited familial AD, it was estimated that Alzheimer’s dementia pathology,
such as amyloid deposition, initiates decades prior to the projected date of disease onset and
that some evidence of cognitive changes is detected years, if not a decade, prior to a dementia
diagnosis [6].
It has been estimated that delaying the onset of Alzheimer’s dementia by one or two years
could decrease global disease burden in 2050 by 11.8 million or 22.8 million cases, respectively
[7]. The emphasis of clinical research has, therefore, begun to shift towards the early clinical
phase of “mild cognitive impairment” (MCI) and even earlier, involving at-risk individuals in
the pre-clinical, thus “prodromal Alzheimer’s dementia”, phases. This allows for primary or
secondary prevention, as well as for disease modification [8] as later stages of established
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disease brain pathology may be too advanced to allow any disease modification or effective
reversal of symptoms. In recent years, there have been several attempts to define this pre-
dementia “prodromal AD” stage, both in its pre-clinical [9, 10] and early symptomatic (or
“MCI due to AD”: MCI-AD) [9, 11] stages, mostly relying on imaging and biomarker data
derived from the analyses of cerebrospinal fluid studies. These criteria, which still require real-
life validation, are mainly intended for clinical research purposes and are not currently applica-
ble in the general population as they are based on technologies and methods that are not easily
accessible.
This prodromal population will largely be unknown to specialist services and therefore
would be suitable for identification from primary care or in the general population. However, it
is widely acknowledged that recruiting individuals into clinical trials is a particularly challeng-
ing endeavour [12–15], with 45% of studies recruiting less than their target and 54% of trials
requiring an extension to fulfil recruitment obligations [16]. Recruitment in primary and sec-
ondary care depends on the active engagement of clinicians to recruit eligible individuals and
often fails to meet the expected targets due to time-pressure in a busy consultation schedule.
Primary care clinicians may also feel that they lack the skills or confidence to give an effective
explanation of a clinical research study. Furthermore, there is recognition that particular
groups of individuals are more challenging to recruit into studies, including young men, the
elderly, those with mental health problems or patients who are socially deprived [17–19]. Pre-
vention studies recruiting healthy volunteers require much larger sample sizes than treatment
trials [20, 21] in order to demonstrate drug efficacy and require different recruitment strategies,
going beyond the traditional “specialised clinic”model. In the USA, Medicare lists or voter reg-
istration rolls have been used to aid recruitment [22, 23], however, such recruitment strategies
may not always be suitable due to ethical and practical considerations. Recruitment into pre-
vention studies may be improved if registers of individuals who are specifically interested in
such studies are available.
Research registers connect potential research participants with research studies, thereby
enabling researchers to successfully recruit large numbers of suitable, motivated participants
and overcome some of the barriers encountered when using traditional methods of recruitment
into clinical trials. Such registers have successfully been used to recruit into treatment trials for
dementia [24] and the Banner Alzheimer’s Institute has initiated a USA-based register of indi-
viduals interested in learning about prevention studies [25]. We sought to leverage the promi-
nent and well-structured role of primary care within the National Health Service (NHS) in the
United Kingdom to develop a primary care based register to address the growing need for
recruitment for clinical studies (including trials) of late-onset dementias. With this in mind, we
established the CHARIOT register (an acronym for Cognitive Health in Ageing Register: Inves-
tigational, Observational and Trial studies in dementia research) as a collaboration between
general practices and researchers within the School of Public Health at Imperial College Lon-
don. The CHARIOT register was designed specifically to support recruitment into observa-
tional or interventional studies for primary prevention trials or secondary prevention strategies
for dementia and other cognitive problems associated with ageing.
Methods
This project was approved by the National Research Ethics Service (NRES) East Midlands–
Derby 1 committee. To join the CHARIOT register, the invitee signed both copies of an
informed consent form and returned these to the register team in a pre-paid reply envelope.
The register has developed in three distinct phases: the initial pilot phase, to establish the
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feasibility and levels of interest in the register; the optimisation phase, during which the opera-
tion of the register was iteratively adapted to maximise response; and the main recruitment
phase.
Recruitment
General practices across the London region were invited to participate in the CHARIOT regis-
ter, and were offered a reimbursement for their involvement. Eligible participants were identi-
fied through searches of general practice records, identifying individuals aged between 60 and
85 and excluding those with a diagnosis of dementia (see Table 1 for an overview of inclusion/
exclusion criteria, and S1 File for the complete list) or those whom the GP or practice staff con-
sidered would be inappropriate to contact. These exclusion criteria follow national guidelines
for identifying patients with a diagnosis of dementia [26]. Patients with early signs of dementia
were considered eligible for joining the register, and were not specifically excluded. Patients
with other chronic health conditions were also considered eligible.
Invitation packs containing an invitation letter, a participant information sheet and two
copies of an informed consent form were printed on GP letter-headed paper and posted to
each invitee at their home address. To join the CHARIOT register, the invitee signed both cop-
ies of the informed consent form and returned these to the register team in a pre-paid reply
envelope. Both consent forms were countersigned by a register investigator, with one copy
being returned to the participant by post, one copy being retained by the register team, and an
additional copy made for the participant’s GP.
The consent procedure was iteratively updated (following ethical approval) in the early opti-
misation stages of the register development. For example, the first version of the informed con-
sent form included an option for the invitee to indicate that they did not wish to join the
register. However, this option was removed following feedback from some invitees querying
the apparent need to reply to the register team if they did not wish to join. The participant
information sheet was also amended to highlight that no action would be required if an indi-
vidual did not wish to join the register, and to reiterate that no information would be shared
without consent. Ethics approval was also obtained to simplify the procedure for the partici-
pant by including a single consent form, a countersigned copy of which was returned to the
participant.
Table 1. List of inclusion/exclusion criteria.
Inclusion Criterion Exclusion Criteria
Individual is aged 60–85 (inclusive) on the date of
search
Individual has a recorded diagnosis of dementia:
• Senile and pre-senile organic psychotic
conditions
• Other alcoholic dementia
• Drug-induced dementia
• Dementia in conditions classiﬁed elsewhere
• Dementia in Alzheimer's disease
• Vascular dementia
• Dementia in other diseases classiﬁed elsewhere
• Delirium superimposed on dementia
• Alzheimer's disease
• Pick's disease
• Senile degeneration of brain
• Dementia with Lewy bodies (DLB)
doi:10.1371/journal.pone.0141806.t001
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Experience from the pilot phase of the register indicated that a number of individuals would
seek to join the register after hearing about it via word-of-mouth. The protocol was therefore
updated to allow “self-referrals” from individuals whose GP was not associated with the regis-
ter. In this case, an invitation pack (on Imperial College London letter-headed paper) would be
sent directly to the individual from the register team. This also included a data collection form
to obtain the data which would otherwise be collected from the GP (see Data Collection sec-
tion). Recruitment through this self-referral pathway relied on individuals self-reporting the
absence of a dementia diagnosis.
Operational changes were also made to the register, including the inclusion of a barcode
screening identifier to assist with the positive identification of individuals where the handwrit-
ing on the consent form was unclear. Manual printing and envelope stuffing was replaced by
automatic production by a third party with NHS Information Governance accreditation (CFH
Docmail, Radstock). This greatly increased the rate at which invitations could be printed and
mailed.
During the pilot phase of the register development, practice administrative staff were asked
to perform the search and prepare the invitation mail-out. However, as the register developed,
the register team were able to provide step-by-step guidance with performing the searches and
preparing the invitation mail-out through the third-party printing company. In all cases, prac-
tice clinical or administrative staff were able to review the list of potential invitees prior to the
mail-out.
During the development of the register’s protocol, it was proposed that, approximately
three weeks after the invitations were posted, a member of the register team would follow-up
with a phone call to invitees who had not returned their consent forms. This would enable
recipients’ questions to be answered and missing or lost consent forms to be re-sent. The ethics
committee recommended that phone calls to individuals should be made by surgery staff, as
sharing these details outside the clinical care team would compromise the individuals’ confi-
dentiality. Therefore, all participating staff at the GP surgeries were trained in the aims and
objectives of the register, were provided with a script approved by the ethics committee, and
were prompted to questions that were likely to be asked by individuals. However, as it was not
possible to monitor the calls, it was difficult to validate the quality and accuracy of the informa-
tion provided and to ensure patients’ queries were answered satisfactorily. Feedback also sug-
gested that availability of surgery staff, expected to carry out the task in addition to their usual
workload, was variable. Furthermore, a review of the phone calls made to invitees at one sur-
gery indicated that of 304 phone calls made by the surgery, 95 were answered and only six of
the patients subsequently returned their consent form. Therefore, it became clear at an early
stage of the register’s development that those individuals who had not responded in writing
were unlikely to subsequently consent to join the register, and that the phone calls represented
a poor use of resources. Therefore, follow-up phone calls were removed from the recruitment
strategy.
Data collection
Participants who agreed to join the CHARIOT register provided consent for their GP to share
a minimum data set from their electronic health record with the register team. This included
contact details (name, address, telephone number and email address), demographic details
(date of birth, sex and ethnicity), along with the participant’s NHS number. No medical infor-
mation was collected. Data were automatically extracted and encrypted at the practice by the
register team, and transferred to a secure database at Imperial College London.
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Participant recruitment to research studies
The aim of the register is to aid recruitment to studies for the prevention of dementia and other
late onset neurodegenerative conditions, and ethically approved studies are reviewed by a sci-
entific review committee. Potential study participants can be identified based on age, gender
and area of residence (based on distance to a study site). The CHARIOT register team contacts
eligible individuals, inviting them to join the study–no data are shared with the other research
teams, unless additional participant consent is obtained. The participant’s GP is not involved
in this stage of recruiting into a follow-up research study, although individual study protocols
may elect to inform the participant’s GP of their involvement.
Data analysis
Descriptive data on the demographic profile of the register participants are reported. However,
as data were only collected for consented individuals, it is not possible to directly compare the
demographics of the CHARIOT cohort with the whole of the invited cohort, therefore these
demographics are estimated from the National General Practice Profiles [27]. Age and gender
profiles are compared against aggregate data from the practice profiles. As ethnicity data is
only available from these profiles at a practice level, without additional detail on age and gen-
der, we use a two-sample t-test to compare the practice-level ethnicity of the register partici-
pants with the profiles. For each practice we then calculate the normalised root mean square
error of the difference between the actual and expected age/gender profile, and use Pearson’s
correlation coefficient (r) to determine if the practices are equally representative, regardless of
the ethnicity of its population.
Pearson’s correlation coefficient was used to examine the correlations between response
rate and the demographic properties of the recruiting GP surgeries. We examined the correla-
tions between response rate and: practice size (based on the list size); the age profile of the prac-
tice (based on the proportion of the list aged 65 years or older); the socioeconomic status of the
practice population (measured by the Index of Multiple Deprivation–IMD); and the ethnicity
of the practice population (indicated by the proportion of White patients registered at the
practice).
Results
The CHARIOT register has developed over a three year period, with three active recruitment
periods between August–October 2011 (pilot phase), March–August 2012 (optimisation
phase), and November 2012 –July 2014 (recruitment phase). During the initial pilot phase,
three surgeries in North West London were approached to gauge the level of interest in the reg-
ister, and a further ten surgeries participated in the optimisation phase. In the final recruitment
phase, 110 surgeries from the wider west and central London geographic area joined the
register.
From the 123 GP surgeries, 109,847 patients were invited to join the register. During the
third recruitment period, a median of 4,690 individuals and a maximum of 7,482 individuals
were invited each month. In total, 24,509 individuals consented to join the register, represent-
ing an overall response rate of 22.3%. Responses per surgery varied between 4.5% and 39.1%
(median 20.2%). Of the individuals who joined the register, 53.3% were female, compared with
an estimate of 52.8% from the National General Practice Profiles.
The median age of participants upon joining the register was 67 years, with a mode at 66
years as shown in Fig 1. Aggregating responses according to the age bands provided by the
National General Practice Profiles allows an estimate of the response rate across the relevant
age bands, as shown in Table 2. The response rate is also shown separately for female and male
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participants in Fig 2, and this shows the expected general decrease in the number of eligible
participants as age increases. The response rates for both women and men appear to be slightly
higher than expected in the 65–69 age group, otherwise the age profile of the register closely
matches the invited cohort.
Ethnicity data were not available for 17.6% of the consented participants. There is also a
lack of comprehensive ethnicity data available at a practice level, with only an approximation
based on patient satisfaction surveys [27]. Therefore, it is difficult to assess how well the register
population reflects the ethnic diversity of the eligible population. However, of the participants
with ethnicity data recorded, 71.9% were White, compared to an estimate of 72.3% from the
practice survey data. The ethnicities of the practices which recruited to the CHARIOT register
were compared with the profiles of practices in the recruiting areas, as shown in Fig 3A. There
was a slight over-representation of practices with larger White populations, although the differ-
ence between the CHARIOT practices and the overall group of practices was not significant
(p = 0.220). The normalised root mean square error of the differences in expected and actual
Fig 1. Age distribution of consented participants.
doi:10.1371/journal.pone.0141806.g001
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age/gender profiles within a practice are shown in Fig 3B. There is a slight trend towards prac-
tices with a larger White population having a smaller error metric, indicating a more represen-
tative age/gender profile, although this trend is not significant (p = 0.175).
Based on these data, it appears that the register population provides a good representation
of the wider population. However, as there was a large variation in the response rate (4.5–
39.1%), we sought to understand the factors which may impact on response by examining the
correlations between response rate and practice demographics–these data are shown in Fig 4.
There was a slight trend towards larger practices having a higher response rate (r = 0.34,
p<0.001), as well as those with an older population (r = 0.27, p = .0003). More significantly,
practices with a higher IMD were correlated with a lower response (r = -0.68, p<0.001). Prac-
tices with a larger proportion of White patients also experienced a higher response rate
(r = 0.82, p<0.001).
At the time of writing, three studies have been approved to recruit through the CHARIOT
register, and these studies will be reported elsewhere as they follow independent clinical proto-
cols. Preliminary data from the first study indicate a response rate of 40.9% of participants con-
tacted about a telephone screening study elected to receive additional information, 44.4% of
whom were subsequently eligible to join the study [28]. The main reason for exclusion was the
requirement for individuals to self-report subjective complaints of memory problems, or other
cognitive difficulties. Of those who enrolled in the study, 22.0% were identified as having
abnormal cognition based on the AD8 Dementia Screening Interview [29] and the Rey Audi-
tory Verbal Learning Test (RAVLT) [30].
Discussion
The CHARIOT register is a novel primary care-based mechanism for recruitment of partici-
pants into research studies for the prevention of AD and other age-related neurodegenerative
diseases. The register has brought together a multidisciplinary team to successfully enrol nearly
25,000 individuals in three years. A number of challenges in recruiting patients from primary
care were identified, including ethical (for example, managing the process for individuals who
do not wish to join the register) and operational challenges (for example, streamlining the pro-
cess for mailing and addressing the challenges of follow-up phone calls).
A response rate of 22% indicates a good resonance with individuals wishing to join the reg-
ister and is comparable to other established research registers. For example, the Scottish Health
Research Register, a centralised register embedded within the health service, had a response
rate of 13% from GP invitation letters [31], and the Hunter Medical Institute Research Register
reported a response rate of 31% [32]. The results from the first study to recruit from the register
show a strong response rate (41%). This provides a compound response rate, accounting for
recruitment into the register and then into study screening, of 9.1%. Although this figure
appears low, it compares favourably with other studies recruiting directly through postal invi-
tations [33]. The high response rate from the register into a study indicates the power of such
Table 2. Age profile of register compared to invited population.
Age Range Estimated Proportion of Eligible Patients [27] Proportion of Consented Participants
60–64 31.8% 27.5%
65–69 23.5% 29.1%
70–74 18.9% 18.9%
75–79 15.0% 14.1%
80–84 10.9% 9.9%
doi:10.1371/journal.pone.0141806.t002
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an established register for other researchers, being able to rapidly recruit large numbers of par-
ticipants into studies. Importantly such an approach does not burden participants’ GPs with
recruitment into studies. Participants who are on the register and may not fulfil inclusion crite-
ria for one study may however be eligible for another–therefore we expect that the total recruit-
ment yield of the register to be ultimately much higher than 9%. Of those individuals who were
screened to join the study, 44% were eligible based on a self-report of early stage symptoms,
such as memory or other cognitive problems. Future studies aimed at a true pre-symptomatic
population are likely to see higher proportions of eligible individuals.
The basic inclusion and exclusion criteria allow us to recruit a representative sample of
the population aged 60–85, excluding only those with an existing diagnosis of dementia. Using
this model there is scope to set up this or similar registers throughout the UK and internation-
ally. This would allow greater access to trials and greater opportunity for researchers to recruit
a highly motivated and willing population. Such expansion could be supported by the
Fig 2. Response rate based on age and gender profiles. The solid lines represent the observed age distribution within the register population, and the
dotted lines represent the expected profile based on the general practice profiles.
doi:10.1371/journal.pone.0141806.g002
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development of a website or mobile/tablet app to improve the ability to communicate with
potential and current participants.
We recognise that this approach has limitations and possible deficiencies. We have recruited
a large number of individuals; however, it is not known how many of the participants may
already have undiagnosed problems with cognition. Due to the age range of participants
invited to join the register, we would expect some participants to demonstrate early signs of the
onset of dementia, and anecdotal evidence from telephone calls received by the register office
suggests that a large number of individuals are worried about their memory. However it is not
clear to what extent this is related to the increasing awareness of the high prevalence of demen-
tia in the older population or to normal age-related memory loss. The mixture of participants
at different stages of disease progression, or none, will allow different prevention studies to tar-
get different disease stages, with follow-on studies screening for specific eligibility criteria. The
first study to recruit from the register indicated 22% of the screened participants with subjec-
tive complaints may have abnormal cognition, therefore enriching the register with other
Fig 3. Ethnicity profiles of participating practices.
doi:10.1371/journal.pone.0141806.g003
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clinical data, including biomarkers, may be a useful strategy [5]. The collection of additional
data may allow improved characterisation of the register population, allowing for stratification
based on dementia risk as a pre-screening tool to select appropriate candidates for specific
inclusion and exclusion criteria of future studies.
To improve the quality of data available, consent may be gathered during recruitment into
the register, allowing collection of additional medical or demographic data from the GP record.
However, this is likely to affect the recruitment rate as individuals may be happy for collection
of the minimal contact and demographic details, but not of their medical data. Extraction of
additional demographic or socioeconomic data from the medical record is also likely to be
hampered by an underlying lack of available data. Our analysis found 17.6% of individuals
joining the register did not have their ethnicity recorded in the medical record, although this
compares favourably with a national review of anonymised centrally-held records which found
this information was not available for 53.8% of patients nationwide [34]. 86% of patients in
England have a smoking status recorded in the health record [26], however other lifestyle data
Fig 4. Correlations between response rate and practice metrics.
doi:10.1371/journal.pone.0141806.g004
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are not routinely collected in general practice in the UK. For example, a review of the collection
of data on alcohol consumption found only 9% of newly registered patients were recorded as
completing a validated screening test [35]. Socioeconomic data at an individual level is unlikely
to be collected, and other studies have also used area-level aggregate data from other sources
[36]. Additional consent may be sought for collection of these additional data directly from
register participants, or for phenotypic characterisation of a sample of the register population
by conducting a battery of cognitive and other tests (for example, neuroimaging), or collection
of biological samples.
In order to address some of the missing data, we have implemented a process for opportu-
nistically collecting missing ethnicity information from participants who have direct contact
with a register team member, principally by telephone. We also have a framework in place for
secondary studies which collect ethnicity data, with appropriate participant consent, to share
these data back to the register. Using these additional ethically approved approaches, we are
progressively building a more complete dataset.
Complete demographic data are not available to provide a comprehensive analysis of
responders compared to non-responders, however, based on practice-level data the register
appears to match the expected age, gender and ethnicity profiles of the wider population.
There was a slight trend towards larger practices having higher response rates, possibly due to
the presence of additional resources available to indirectly support recruitment. Larger prac-
tices are likely to have additional administrative staff who can support the direct recruitment
tasks, rather than relying on the involvement of practice managers or general practitioners
themselves, as well as having more developed organisational procedures in place [37]. Lower
response rates were associated with practices with higher IMDs, and larger Black and Minority
Ethnic populations. Although a representative sample was obtained overall, this highlights the
challenges of recruiting participants from these groups. Due to the cultural and linguistic diver-
sity in the recruitment region, further recruitment strategies may be augmented by including
recruitment material in alternative languages.
The CHARIOT register has been successfully established, consisting of a large cohort of
individuals interested in participating in dementia prevention research. Response rates of indi-
viduals consenting to join the register indicate interest and support for a research register and
for participation in research for the prevention of age-related neurodegenerative diseases and
dementia. The simplicity of this approach means that this system is easily scalable, increasing
the availability of participants and the ease of recruiting participants for research studies into
the prevention of dementia.
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